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’ INTRODUCTION
Regenerative medicine studies offer promising therapeutic
approaches for the repair of damaged tissues. Induction of angio-
genesis (new vessel formation) is an important mechanism for
tissue repair.1 The capillaries can only deliver oxygen and nutrients
to the cells that are located at a distance of up to 200 μm, and thus
angiogenesis is required for cells further away during new tissue
formation.2 Angiogenesis is triggered by the detection of neo-
vascularization signals by endothelial cells, which in turn differ-
entiate to form new capillaries. Structural proteins of the extra-
cellular matrix (ECM) (laminin, collagen, etc.), growth factors
(VEGF, FGF-2, etc.), and glycosaminoglycans (heparan sulfate,
etc.) make up a framework for detection of neovascularization
signals by endothelial cells. Understanding the interactions
between these biomolecules during angiogenesis and their roles
in the regulation of angiogenic processes paves the way to design
synthetic biomaterials that can mimic the bioactivity of natural
materials.
Conventional tissue engineering strategies utilized some of the
biological molecules mentioned above to provide bioactivity for
promoting angiogenesis3 because synthetic biomolecules that
have been produced so far lacked the ability to mimic the func-
tions of all of these biological components. The main motivation
for developing new synthetic ECM mimicking biomaterials is to
minimize utilization of the above-mentioned natural biomacro-
molecules exogenously with the aim of reducing cost, preventing
batch-to-batch variation, and avoiding biological contamination.
Therefore, designing smart biomaterials that can manipulate
endogenous factors for desired bioactivity is essential. Recent
research efforts have focused on developing new scaffold materi-
als with proper functional groups that are sufficient to induce the
desired physiological response in vitro without any need for
growth factors or any other supplements.4
Among the basic components of the framework that aids in the
detection of neovascularization signals by endothelial cells,
heparan-sulfate proteoglycans (HSPGs) bind to angiogenesis-
promoting growth factors and their receptors through heparan
sulfate chains and regulate growth factor signaling.58 Mice
lacking heparan sulfate chain on HSPGmolecule reveal defective
angiogenesis and wound healing.9 Binding of growth factors
to HSPGs, which strictly depends on the distribution of func-
tional groups, such as sulfate, hydroxyl and carboxyl groups, on
heparan sulfate chains, protects growth factors from degradation,
increases local concentration of growth factors, and enhances
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ABSTRACT:New blood vessel formation (angiogenesis) is one of the most important
processes required for functional tissue formation. Induction of angiogenesis is usually
triggered by growth factors released by cells. Glycosaminoglycans (e.g., heparan sulphates)
in the extracellular matrix aid in proper functioning of these growth factors. Therefore,
exogeneous heparin or growth factors were required for promoting angiogenesis in
previous regenerative medicine studies. Here we report for the first time induction of
angiogenesis by a synthetic nanofibrous peptide scaffold without the addition of any
exogenous growth factors or heparin. We designed and synthesized a self-assembling
peptide amphiphile molecule that is functionalized with biologically active groups to
mimic heparin. Like heparin, this molecule has the ability to interact with growth factors
and effectively enhance their bioactivity. The nanofibers formed by these molecules
were shown to form a 3D network mimicking the structural proteins in the extracellular
matrix. Because of heparin mimicking capabilities of the peptide nanofibers, angiogen-
esis was induced without the addition of exogenous growth factors in vitro. Bioactive interactions between the nanofibers and the
growth factors enabled robust vascularization in vivo as well. Heparin mimetic peptide nanofibers presented here provide new
opportunities for angiogenesis and tissue regeneration by avoiding the use of heparin and exogenous growth factors. The synthetic
peptide nanofiber scaffolds enriched with proper chemical functional groups shown in this study can be used to induce various
desired physiological responses for tissue regeneration.
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growth factorreceptor interactions, which are important for
long-term stimulation of signaling pathways in endothelial
cells.8,1012 Using glycosaminoglycans (e.g., heparin) within
tissue engineering scaffolds has been shown to enhance angio-
genesis significantly while reducing the need for exogenous growth
factors in in vivo studies.13,14 However, being an animal-derived
product, utilization of heparin in tissue engineering systems
might have potential side effects (e.g., immune reactions).15
Designing heparin mimetic biomaterials will have high impacts in
cellular therapy and regenerative medicine because they will
enable us to avoid the use of heparin while minimizing the use of
exogenous growth factors.
Peptide-based scaffolds are promising candidates for design-
ing smart biomaterials because they are suitable for attachment of
various bioactive chemical groups along with their biocompat-
ibility. A peptide amphiphile (PA) scaffold for angiogenesis was
previously developed by mixing heparin-binding PA molecule
and heparin.13 Heparin-binding PA molecule allowed growth
factor binding and helped the formation of various functional
tissues.13,16,17 The addition of functional groups inspired by
heparin on peptide sequences and polymers has also been pre-
viously shown to enhance growth factor binding capacity.1822
For example, sulfated alginate polymers gained growth factor
binding capability and induced in vivo angiogenesis significantly
better than nonsulfated alginate in the presence of growth
factors.19,23
In this study, we designed and synthesized a heparin-mimetic
PA molecule functionalized with bioactive groups for mimicking
heparin activities. The heparin-mimetic PA molecules self-as-
semble to form nanofibers with abilities to bind to growth factors
and to promote angiogenesis without the need for the addition of
exogenous heparin or growth factors. This work demonstrates
that nanostructures with bioactive chemical groups inspired by
biological macromolecules can be used to activate biological
machinery for regenerative medicine applications.4,24
’EXPERIMENTAL SECTION
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxy-
carbonyl (Boc) protected amino acids, [4-[α-(20,40-dimethoxyphenyl)
Fmoc-aminomethyl]phenoxy]acetamidonorleucyl-MBHA resin (Rink
amide MBHA resin), Fmoc-Asp(OtBu)-Wang resin, and 2-(1H-Benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
were purchased fromNovaBiochem and ABCR. Heparin was purchased
from Sigma-Aldrich. The other chemicals were purchased from Fisher,
Merck, Alfa Aesar, or Aldrich. All chemicals were used as provided.
VEGF (vascular endothelial growth factor) used in angiogenesis assays
were purchased from Sigma-Aldrich (mouse) and Invitrogen (human).
Bothmouse and human bFGFs (fibroblast growth factor) (FGF-2) were
purchased from e-Biosciences.
Synthesis of Peptide Amphiphiles. PAs were constructed on
Rink Amide MBHA resin or Fmoc-Asp(OtBu)-Wang resin. Amino acid
couplings were performed with 2 equiv of Fmoc-protected amino acid,
1.95 equiv of HBTU, and 3 equiv ofN,N-diisopropylethylamine (DIEA)
for 2 h. Fmoc removal was performed with 20% piperidine/dimethyl-
formamide solution (DMF) for 20 min. We used 10% acetic anhydride
solution in DMF to block remaining free amine groups after amino acid
coupling. After each step, resin was washed by using three times DMF,
three times DCM, and three times DMF, respectively. Sulfobenzoic acid
was added to the side chain of lysine to synthesize sulfonated PAs.
A lysine residue with 4-methytrityl (Mtt) side-chain protection was used
for selective deprotection of amine groups. Mtt removal was performed
by shaking resins for 5 min with TFA/TIS/H2O/DCM in the ratio of
5:2.5:2.5:90. Cleavage of the PAs from the resin was carried out with a
mixture of TFA/TIS/H2O in the ratio of 95:2.5:2.5 for 2 h. Excess TFA
was removed by rotary evaporation. The remaining viscous PA solution
was triturated with ice-cold ether, and the resulting white precipitate was
dried under vacuum. PAs were characterized by liquid chromatogra-
phymass spectrometry (LC-MS). Mass spectrum was obtained with
Agilent 1200 LC-MS equipped with Agilent 6530 Q-TOF with an ESI
source and Zorbax Extend-C18 2.1  50 mm column for basic con-
ditions and Zorbax SB-C8 4.6 mm  100 mm column for acidic
conditions. A gradient of (a) water (0.1% formic acid or 0.1% NH4OH)
and (b) acetonitrile (0.1% formic acid or 0.1% NH4OH) was used.
Agilent 1200 preparative reverse-phase HPLC system equipped with a
Zorbax Extend-C18 21.2  150 mm column for basic conditions and a
Zorbax SB-C8 21.2 150 mm column for acidic conditions was used to
purify the peptides. A gradient of (a) water (0.1% TFA or 0.1%
NH4OH) and (b) acetonitrile (0.1% TFA or 0.1% NH4OH) was used.
Peptide Amphiphile Nanofiber Formation. To investigate
angiogenic potentials of PA nanofibers presenting heparin-mimicking
functional groups, we designed and synthesized several PA molecules.
Functional group content varied for each molecule: Heparin-mimetic
PA was synthesized with sulfonate, hydroxyl, and carboxylic acid groups,
SO3-PAwith sulfonate and carboxylic acid groups, and Asp-PAwith only
carboxylic acid groups (Figure 1). To induce gel and nanofiber forma-
tion, we prepared PA formulations by mixing Heparin-mimetic PA,
Asp-PA, and SO3-PA molecules with Lys-PA at 1:2, 1:1, and 1:1 molar
ratios, respectively. His-PA solution was adjusted to pH 7.4, and heparin
was mixed with Lys-PA at ∼1:8 molar ratios.
AFM Imaging of PA Nanofibers. AFM sample solutions were
dropped on the silicon wafer surface and mixed by pipetting up and
down. We mixed 25 μL of 0.02 wt % Heparin-mimetic PA or equimolar
concentrations of SO3-PA and Asp-PA with 25 μL of 0.02 wt % positively
charged Lys-PA. Heparin was mixed with Lys-PA, and His-PA solution
was adjusted to pH 7 for nanofiber formation. After 30 s, solvent on the
wafer was removed by using dust-free tissue paper, and the rest was air-
dried. Contact mode atomic force microscopy (AFM) was performed by
using model MFP-30 from Asylum Research. All images were taken with
0.5 Hz scan rate. Tips with resonance frequency of 13 kHz and spring
constant of 0.2 N/m were used in all experiments.
SEM Imaging of PA Gels. PA gels (1 wt % Heparin-mimetic PA
gel and equimolar amount for the rest) were transferred onto a metal
mesh, and network dehydration was performed by incubating gels for
30 s in 20, 40, 60, 80, and 100% ethanol sequentially. Then, gels were
critical-point dried by using Autosamdri-815B (Tousimis). Dried gels
were coated with 6 nm of Pt. SEM (FEI Quanta 200 FEG) images were
taken by using ETD detector at high vacuum mode with 30 keV beam
energy.
TEM Imaging of PA Nanofibers and Nanofiber Size Mea-
surements. PA nanofiber size measurements were made according to
TEM images for each nanofiber type (Figure 2).25 TEM sample was
prepared bymixing Heparin-mimetic PA, SO3-PA, and Asp-PA (1 wt %)
with Lys-PA (1 wt %). Gel was diluted 10 times, and 30 μL from this
solution was dropcasted onto a hydrophobic surface. TEM grid was
placed onto droplet and incubated for 3 min. Staining was performed
with 2% uranyl acetate. Nanofiber diameters were measured by Image J
software (NIH).
SEM Imaging of Cells on the PA Gels. In vitro tube formation
experiment was performed (as described above) on round glass cover-
slips located in 24-well plates. After 48 h, media on cells were aspirated,
and cells were washed with 1 PBS twice. Cells were fixed with 2%
glutaraldehyde 1 h prior to fixation with 1% osmium tetroxide (OsO4).
After network dehydration, critical-point drying was performed as described
above for SEM imaging of PA gels. Samples were coated with 6 nmAuPd
coating, and SEM imaging was performed as described above.
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Isothermal Titration Calorimetry. To investigate the interac-
tion between VEGF and PAs, we used the iTC200 system (MicroCal, GE
Healthcare). VEGF titration (6.25 μM) into four different PA solutions
(0.08 mM) was performed on Heparin-mimetic PA (solution form),
Heparin-mimetic PA with Lys-PA (nanofiber form), Asp-PA (solution
form), and Asp-PA with Lys-PA (nanofiber form). VEGF into H2O and
H2O intoHeparin-mimetic PAwith Lys-PA titrations were performed as
control to eliminate dilution heats. Reaction was performed at 30 C
with 400 rpm stirring speed. Twenty-five injections were performed,
where the injection period was 4 s and space between injections was 200
s. The data were integrated and fit to a curve with MicroCal Origin
software to calculate the binding constant. For VEGF to PA solution
titrations, best-fitting was obtained with one set of sites model, whereas
for VEGF to PA nanofiber titrations, best-fitting was obtained with
sequential binding sites model, and overall binding constant was
calculated. To determine supramolecular heparin-mimetic system con-
centration, we performed calculations based on approximations made by
Silva et al.26 (average diameter of fiber disk = 6 nm; circumference of
nanofiber (Πd) = 18.8 nm, number of PA molecules/radial disk = 50).
Width of radial disk ≈ size of 1 molecule = 18.8 nm/50 = 0.376 nm. A
100 nm length PA nanofiber can contain∼13 300 PAmolecules with 50
PA molecules per radial disk and 0.376 nm width.
Heparin mimetic PA and Lys-PA were mixed at 1:2 molar ratio.
Therefore, the number of Heparin mimetic PA molecules per 100 nm
Figure 1. Chemical structures of peptide amphiphiles (PAs) used in this study: (A) Heparin-mimetic PA, (B) SO3-PA, (C) Asp-PA, (D) Lys-PA, and
(E) His-PA.
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nanofiber was calculated to be 13 300/3 = 4433 molecules. By assuming
that the average nanofiber length was 100 nm, nanofiber concentration =
0.08 mM/4433 = 1.8 105 mM. Asp-PA and Lys-PA were mixed with
1:1 molar ratio. The number of Asp-PA per 100 nm nanofiber was
calculated to be 13300/2 = 6650 molecules. By assuming that average
nanofiber length was 100 nm, nanofiber concentration = 0.08 mM/6650 =
1.2 105 mM. The nanofiber dimensions were also measured by using
TEM imaging, as described above. All solutions that were used in ITC
experiments were at pH 7.
To investigate the interaction between heparin and Lys-PA, heparin
(100 μg/mL) was titrated into Lys-PA solution (40 μg/mL). Reaction
was performed at 30 C with 400 rpm stirring speed. Twenty-five
injections were performed, where injection period was 4 s and space
between injections was 150 s. The data were integrated and fit to a curve
with MicroCal Origin software to calculate the binding constant. Best-
fitting was obtained with one set of sites model.
Oscillatory Rheology. Oscillatory rheology measurements were
performed with an Anton Paar Physica RM301 rheometer operating
with a 25 mm parallel plate configuration at 25 C. Each sample of 180 μL
total volumewith a final PA concentration of 1 wt % heparin-mimetic PA
or equimolar concentrations for other PAmolecules was carefully loaded
on the center of the lower plate and incubated for 15 min before mea-
surement. After equilibration, the upper plate was lowered to a gap distance
of 0.5 mm. Storage moduli (G0) and loss moduli (G00) values were scanned
from 100 to 0.1 rad/s of angular frequency, with a 0.5% shear strain.
Circular Dichroism. JASCO J815 CD spectrometer was used at
room temperature. We measured 2  104 M peptide solutions from
300 to 190 nm, data interval and data pitch were 0.1 nm, scanning speed
was 100 nm/min, and all measurements were performed with three
accumulations. DIT was selected as 1 s, bandwidth as 1 nm, and the
sensitivity was standard. Molar ellipticity was calculated using the equation:
[θ] = 100 θ/(C l), where C is the concentration in molar, and l is the
cell path length in centimeters. [θ] = θ/(C l) = deg/(mol/1000 cm3)
0.1 cm = 10 cm 103 deg 1000 cm3 mol1 = 100 deg cm2 dmol1.
Zeta Potential Measurement. The zeta potential of equimolar
PA solutions (0.16 mM) and heparin (0.5 mg/mL) was measured by
Nano-ZS Zetasizer (Malvern). Zeta potential converts measured mobi-
lity to zeta potential by using Smoluchowski equation. After measuring
zeta potential of each PA solution, Lys-PA was mixed with Heparin-
mimetic PA (2:1 molar ratio), SO3-PA (1:1 molar ratio), Asp-PA (1:1
ratio), or heparin and the zeta potential of the solution was measured
again. Molar ratios were the same as those used for cell culture and other
experiments (net 1 charge for each combination).
Cell Lines and Cell Culture Reagents. H5V mouse endothelial
cells27 were a kind gift from Dr. Annunciata Vecchi, Instituto Clinico
Humanitas, IRCCS, Rozzano, Milano, Italy. Human umbilical vein
endothelial cells (HUVECs) were donated byYeditepeUniversity, Istanbul,
Turkey. HUVECs were purified as described28 and were characterized
by staining with CD34, CD31, and CD90 surface markers. These cells
were found to be positive for CD31 and CD34 but negative for CD90.
All media, sera, and other cell culture reagents were purchased from
Invitrogen. Matrigel was purchased from BD Biosciences.
In Vitro Angiogenesis Assay. Equimolar concentrations of PAs
(0.2 wt % for Heparin-mimetic PA and equimolar amount for the rest)
were used to form gels in 96-well plates. Coated plates were incubated at
37 C for 30 min, prior to overnight incubation in laminar flow hood at
Figure 2. Characterization of peptide amphiphile nanofiber matrices by using SEM, AFM, and TEM. Imaging studies revealed that the gels that were
formed by the PA molecules had similar structural properties in terms of individual fibers and formation of nanofibrous networks. SEM images of
Heparin-mimetic PA (A), Asp-PA (B), and SO3-PA (C). AFM images of Heparin-mimetic PA (D), Asp-PA (E), and SO3-PA (F). TEM images of
Heparin-mimetic PA (G), Asp-PA (H), and SO3-PA (I).
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room temperature for solvent evaporation. The next day, PA matrix
formed on 96-well plates was UV-sterilized, and endothelial cells were
cultured on these matrices or Matrigel, which was used as a positive
control. HUVECs cultured in DMEM with 10% FBS (growth medium)
were collected at 8090% confluency and resuspended in DMEM with
5% FBS for angiogenesis assay. Cell number was adjusted to 2  105
cells/mL, and 200 μL of this suspension was added to each well either
alone ormixedwith low (10 ng/mL) or high dose (50 ng/mL) of VEGF/
bFGF combination. After 48 h, cells were imaged by using bright-
field microscopy at 100 magnification. For fluorescence imaging,
media over cells were aspirated, and cells were washed with PBS.
Calcein solution (2 μM, 100 μL) was added to cells and incubated for
30 min at 37 C. Cells were imaged with fluorescence microscopy.
Mouse endothelial cells (H5V) were also grown in DMEM with 10%
FBS until 8090% confluency. Cells were collected and resuspended in
minimal essential media (MEM) with 2% FBS during angiogenesis
assay. Cell numbers were adjusted to 3  105 cells/mL. We added
100 μL from this suspension (3  104 cells) to each PA matrix either
alone or mixed with growth factors (VEGF/bFGF). Cells were incu-
bated for 48 h, and imaging was performed by using bright field
microscopy. All of the in vitro experiments and other measurements
were performed at least three times.
Cell Proliferation Assay. 96-well plates were coated with PA
matrices, as described, or left uncoated (TCP). HUVEC (1 104) were
added to each well in DMEM with 10% FBS. BrdU-based kit (Roche)
was used to evaluate cell proliferation at the end of 54 h. In brief, 16 h
before ending an experiment, BrdU was added to each well. After 16 h,
cells were fixed and stained by using labeled antibody against BrdU. Cells
were washed three times with PBS, and substrate solution was added.
After 5, 10, and 20 min, color development was measured at 370 nm
by using microplate reader (Molecular Devices) and subtracted from
reference wavelength (492 nm) values.
Quantification of in Vitro Tube Formation. In total, 12 images
(100 magnification) were taken for each treatment group (four different
images per well). Quantification of endothelial tube lengths on each
image was performed by using NIH Image J software according to
previously published criteria.29 Tube length values obtained for each well
(three wells per treatment group) were summed, and mean value of data
obtained from three wells was calculated. Two-way ANOVA was used
for statistical analysis.
Growth Factor Release from PA Gels. Heparin-mimetic PA,
Asp-PA, and heparin solutions were combined with Lys-PA (premixed
with 100 ng of VEGF) to induce gel formation (1 wt % for Heparin-
mimetic PA gel and equimolar amount for the rest). After 1 h of
incubation at 37 C, 250 μL of 1 PBS was added to each gel. Buffer
over gels was collected and replaced with fresh buffer at four different
time points (2, 24, 72, and 168 h). VEGF released in the buffer solutions
were quantified by ELISA method. VEGF incubated in same buffer
solution (without gel) was accepted as 100% release.
Real-Time Gene Expression Study. HUVECs (3  105 cells/
well) were cultured on bare tissue culture plate (NC), Heparin-mimetic
PA, orAsp-PAnanofibermatrices (as described in the InVitroAngiogenesis
Assay section) for three different durations (6, 24, and 48 h). Total
RNAs were extracted from cells by using TRIzol (Invitrogen) according
to the manufacturer’s instructions. Concentration and purity of isolated
RNAs were measured by Nanodrop. Samples were diluted to a
concentration of 50 ng/μL prior to their use. RNAs were converted to
cDNA and amplified by using SuperScript III Platinum SYBR green one
step qRT-PCR Kit (Invitrogen). Primer sequences for each gene are
given in Table S3 of the Supporting Information. Specificity of ampli-
fications was determined by the presence of single peaks/gene inmelting
curve analysis and detection of the product size by running PCR
products in 1.5% agarose gel. Gene expression levels were normalized
with GAPDH expressions for each sample, and relative expressions were
calculated by 2ΔΔCtmethod according to the below formula:ΔCt (NC) =
(Ctgene  Ctreference); ΔCt (PA-coated) = (Ctgene  Ctreference); ΔΔCt =
ΔCt (PA nanofiber-coated)  ΔCt (NC); fold expression =2ΔΔCt; %
change in expression: 100  2ΔΔCt.
Detection of VEGF Secretion by Endothelial Cells.HUVECs
were cultured at a density of 4 104 cells/well on different PA matrices
and bare tissue culture plates, as described above (In Vitro Angiogenesis
Assay section). Supernatants were collected at three different time
points (12, 24, and 48 h). Concentration of VEGF in these supernatants
was quantified by ELISA method (Invitrogen). Two-way ANOVA was
used to determine the significance of difference between VEGF secre-
tion amount from cells cultured on PA matrices or tissue culture plate.
In Vivo Corneal Micropocket Angiogenesis Assay. Animal
model and experimental setup were approved by the Animal Ethics
Committee of Fatih University Medical School. The in vivo assay was
carried out with 200220 g female SpragueDawley rats. A surgical
micropocket was opened in the cornea ∼1.5 mm from the limbus
under anesthesia, as described.13 Three conditions were tested with this
model: 1 wt % Heparin-mimetic PA gel with 10 ng bFGF and VEGF;
growth factor solution including 10 ng bFGF and VEGF; and 1 wt %
Heparin-mimetic PA gel without growth factors. Gels were made in situ
by mixing Heparin-mimetic PA and Lys-PA. Eleven days after injection,
rats were anesthetized with xylazine/ketamine solution and perfused
through injection of India ink to the left ventricular region of their hearts
to observe integration of newly formed vessels into the circulatory
system. Quantification of vascularization as a response to each treatment
(n = 3 per group) was done with NIH Image J software according to
previous work.13 Student’s t test was used for statistical analysis of
difference between treatment groups. DC-1 digital camera (Topcon
Europe, Ijssel, The Netherlands) was used for imaging the cornea.
’RESULTS AND DISCUSSION
To recapitulate natural extracellular environment that induces
angiogenesis, we designed PA molecules that can mimic GAG
molecules to enable enhanced functioning of the growth factors
that are crucial for angiogenesis. Heparin-mimetic PAmolecule is
decorated with carboxylic acid, hydroxyl, and sulfonate groups to
mimic heparin (Figure 1a and Figure S1a of the Supporting
Information). To assess the importance of each of these func-
tional groups during angiogenesis process, we synthesized other
PA molecules that contain only one or two of these groups. SO3-
PA and Asp-PAwere designed to control the bioactivity of sulfonate
groups and carboxylic acid groups, respectively (Figure 1b,c). His-
PA was designed as a neutral PA molecule at physiological pH to
control the effect of a nonbioactive PA gel during angiogenesis
(Figure 1e), and heparin was mixed with Lys-PA (Lys-PA/
heparin) to observe the effect of heparin on bioactivity of the
PA gel (Figure 1d). All PA molecules were purified with HPLC
(Figure S1b, S2a, S3a, S4a, and S5a of the Supporting Information)
and inspected with mass spectrometry (Figures S1c, S2b, S3b,
S4b, and S5b of the Supporting Information). The abilities of
these molecules to form a network, that can mimic the structural
properties of the natural ECM,30 were analyzed by SEM imaging.
All PA molecules that were analyzed exhibited a nanofibrous
network that is suitable for providing the necessary mechanical
support for cells (Figure 2ac and Figure S6a,b of the Support-
ing Information). AFM imaging of these nanofibrous structures
enabled visualization of the nanofibers that make up these ECM-
like networks (Figure 2df and Figure S6c,d of the Supporting
Information). The nanofibers formed by PA molecules were also
imaged by AFM and TEM (Figure 2 and ref 25). Nanofiber
sizes for different PA combinations are provided in Table S1
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of the Supporting Information. Nanofiber diameters for Heparin-
mimetic PA/Lys-PA, Asp-PA/Lys-PA, Lys-PA/heparin, and His-
PA samples do not differ significantly.
Mechanical properties of the extracellular environment are
crucial for determining cell fate, and thus we compared the
gels by using oscillatory rheology to understand whether the
differences in their bioactivities were caused by variations
in their mechanical properties (Figure 3a). Each of the gels
(Heparin-mimetic PA/Lys-PA gel, SO3-PA/Lys-PA gel, Asp-
PA/Lys-PA gel, and Lys-PA/heparin gel) had storage modulus
(G0) higher than loss modulus (G00), indicating gel formation.
Storage moduli, showing stiffness of the gels, were in the same
order of magnitude for all gels designed for this study. Further-
more, loss tangents (tan δ = G00/G0) of all materials were com-
pared, which provides information about viscoelastic character of
the gels and their gelation properties.31,32 These values were
found to be comparable in all of the PA gels tested here (Table S2
of the Supporting Information). Structural properties of the gels
were also analyzed with circular dichroism (CD) spectroscopy.
The CD spectra of all of the PAs demonstrated β-sheet secondary
structure (Figure 3b). Therefore, the structural properties of the
gels were found to be comparable as well.
Zeta potentials for PA solutions were measured to understand
the charge of the peptide systems. Zeta potentials of the PA
solutions were measured, and the self-assembled nanostructures
were measured upon the addition of oppositely charged Lys-PA
(Figure S14 of the Supporting Information). All carboxylate and
sulfonate functionalized PAs and heparin revealed negative
potentials. When Lys-PA solution with a positive potential was
added to the aforementioned solutions, overall charge in all solu-
tions revealed negative potentials. Molar ratios of these mixtures
were adjusted so that net charge of the system will be negative.
Heparin-mimetic PA/Lys-PA and SO3-PA/Lys-PA combina-
tions had similar potentials, nearly 30 mV, whereas Asp-PA/
Lys-PA potential decreased to 5 mV. We observed a similar
trend in heparin and Lys-PA mixture, where potential of heparin
solution decreased from 60 to 45 mV. This observation can
be related to the presence of sulfonate (SO3) group inHeparin-
mimetic PA, SO3-PA, and heparin. Sulfonate group’s pKa (∼1) is
lower than carboxylate group’s (∼5), making charge neutraliza-
tion of Asp-PA easier than that of sulfonate-bearing PAs. There-
fore, the presence of sulfonate group increases the negative
charge density on PA nanofibers, which might have an activatory
role in growth factor binding. However, SO3-PA nanofibers
and heparin/Lys-PA did not reveal bioactivity compared with
Heparin-mimetic PA nanofibers, as discussed below. Therefore,
the specificity of growth factor binding to PA nanofibers is not
only related to the charge of the system. Moreover, growth factor
release rates from Lys-PA/heparin gel shown in Figure 8 were
Figure 3. (A) Rheology measurements. Storage and loss moduli of
equimolar PA gels that were measured with oscillatory rheometry,
revealed that the mechanical properties of the gels were similar. (B)
Circular dichroism analysis. Circular dichroism spectra of Heparin-
mimetic PA and Asp-PA molecules mixed with Lys-PA show character-
istic β-sheet structure in all of the samples.
Figure 4. In vitro angiogenesis assay. Bright-field images of HUVECs were cultured on Matrigel (A), Heparin-mimetic PA nanofiber matrix (B), Asp-
PA nanofiber matrix (C), and bare tissue culture plate (D) and followed for 48 h to assess migration and tube formation. Live-dead assays revealed that
HUVECs grown on these matrices showed similar viability profiles: matrigel (E), Heparin-mimetic PA nanofiber matrix (F), Asp-PA nanofiber matrix
(G), and bare tissue culture plate (H). All images were taken at 100 magnification. (n = 3 for all conditions).
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significantly faster than those from Heparin-mimetic PA gel and
Asp-PA gel, which is also related to specificity of the nanofiber
and growth factor interactions.
The angiogenic potential of the heparin-mimicking peptide
nanofibers was investigated by culturing HUVECs on PA nano-
fibers decorated with functional groups inspired by heparin
(Figure 4).WhenHUVECs are cultured on basement membrane
gel, which consists of natural ECM proteins as well as various
growth factors (Matrigel), cells coalesce on the matrix forming
capillary-like structures (Figure 4a). Cells cultured on Heparin-
mimetic PA (Figure 4b) matrix also formed capillary-like struc-
tures; however, although this matrix is synthetic and does not
contain any growth factors or GAG molecules, no addition of
exogenous growth factors was needed for the formation of these
capillary-like structures.33 SO3-PA and Asp-PA matrices slightly
induced migration of cells compared with Heparin-mimetic PA,
forming a few tube-like structures (Figure 4c and Figure S7 of the
Supporting Information). Lys-PA/heparin and His-PA matrices
did not induce any angiogenic activity, where cells on these
matrices acted similar to cells on bare tissue culture plates
(Figure 4d and Figure S7 of the Supporting Information). The
lack of angiogenic activity on His-PA matrices shows that the
uncharged nanofiber structure is not a determinant for induction
of angiogenesis. Cells were also stained with Calcein AM, which
is degraded in metabolically active cells producing fluorescence.
This assay revealed that the cells that formed capillary-like
structures as well as the cells that were cultured on basement
membrane, control PA gels, and tissue culture plate were
metabolically active (Figure 4eh).
To analyze whether Heparin-mimetic PA had any effect on
proliferation of endothelial cells, BrdU-based proliferation assay
was used (Figure S9 of the Supporting Information). The results
revealed that all of the PA nanofibers utilized in this study
exhibited similar effect on the proliferation rates of endothelial
cells compared with that of tissue culture plate. Therefore, it can
be concluded that Heparin-mimetic PA induces cellular migra-
tion, sprouting, and tube formation by the endothelial cells,
however, neither induces nor impedes cellular proliferation.
When average lengths of the capillary-like formations were
quantified, Heparin-mimetic PAmatrix was found to be the most
effective matrix for angiogenesis formation compared with base-
mentmembrane and other controls. Among the twomost potent
matrices, Heparin-mimetic PA and Asp-PA, Heparin-mimetic PA
enhanced tube formation capability of HUVECs nearly four
times more than Asp-PA (Figure 5). The other PA nanofibers
also demonstrated poor angiogenesis activity because of the
deficiency of functional groups (Figure S7 of the Supporting
Information). The lack of angiogenic activity observed on
Lys-PA/heparin matrices is potentially due to suppression of
heparin’s bioactivity because of nonspecific electrostatic binding.
Similar nonspecific binding between lysine-containing PA mol-
ecules and heparin was previously observed.14 In that study,
scrambled PAmolecule with several lysine residues was shown to
bind to heparin nonspecifically, masking heparin’s bioactivity.
The interaction between the Lys-PA and heparin was also
observed by ITC measurement (Figure S12 of the Supporting
Information). The binding interaction between Lys-PA and
heparin was driven mainly by enthalpic reactions (ΔH = 7.2 
105 ( 5.1  104, ΔS = 2390) similar to the scrambled PA
molecule and heparin observed by Rajangam et al.14 The addition
of exogenous growth factor combination (VEGF/FGF-2) to the
culture media did not change tube formation potential of any of
the other matrices, which indicates that presence of a fibrous
matrix and growth factors are not sufficient for angiogenesis
(Figure 5B and Figure S7 of the Supporting Information).
Previously, a difference in angiogenic activity between a hepar-
in-binding PA and its scrambled sequence was also observed,
emphasizing the importance of appropriate presentation of
heparin to growth factors and cells.14
In vitro tube formation potential of Heparin-mimetic PA nano-
fiber matrix was further investigated by using H5V cell line (mouse
endothelial cell line).27 Similar to HUVECs, H5V cells also formed
capillary-like structures on Heparin-mimetic PA matrices after 24 h
of culturing, whereas they did not form tubes on Asp-PA and SO3-
PA matrices (Figure S8 of the Supporting Information). These
results suggest that the presence of all three functional groups in
Heparin-mimetic PA is necessary for in vitro angiogenesis formation.
Figure 5. Quantification of tube lengths formed by endothelial cells
(HUVECs). (A) Quantification of tube lengths by HUVEC cultures on
Matrigel, Heparin-mimetic PA gel, Asp-PA gel, or tissue culture plate
(TCP). Statistical differences between groups were analyzed by one-way
ANOVA test. Bonferroni’smultiple comparison test was used as posthoc
analysis. p < 0.001 between Heparin-mimetic PA gel and Asp-PA gel or
TCP. p < 0.05 between Heparin-mimetic PA gel and Matrigel. (B)
Graph illustrates quantification of tube lengths for different growth
factor treatment conditions (most potent two scaffolds are shown). Low
dose: 10 ng/mLVEGF/FGF-2, high dose: 50 ng/mLVEGF/FGF-2. p <
0.001 between Heparin-mimetic PA and Asp-PA scaffolds (analyzed by
two-way ANOVA) (n = 3 for all conditions).
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The cells on PA matrices were also imaged by SEM to analyze
the effects of Heparin-mimetic PA nanofibers on endothelial cells
(Figure 6, Figure S10 of the Supporting Information). The
Heparin-mimetic PA matrix was observed to facilitate cell
attachment and spreading compared with cells grown on tissue
culture plate (Figure 6 and Figure S10 of the Supporting Infor-
mation).34 Moreover, Heparin-mimetic PA matrix allowed
cellcell interactions and polygonal structure formation, which
is a characteristic sign of in vitro angiogenesis (Figure 6).35
Endothelial sprouting and tubules extending on and inside the
PA matrix further support the suitability of Heparin-mimetic PA
matrix for endothelial cell activities (Figure 6 and Figure S10 of
the Supporting Information).
As previouslymentioned, glycosaminoglycans regulate growth
factorreceptor interactions in the natural cellular environment.
For example, VEGF cannot affect endothelial cells when there is
no glycosaminoglycan in the microenvironment.7,11 Therefore,
induction of angiogenesis by Heparin-mimetic PA nanofibers is
potentially caused by their ability to bind to and present the
growth factors that are secreted by the endothelial cells, which is
critical for long-lasting angiogenic signaling process.11 Specific
growth factor binding to Heparin-mimetic PA nanofibers was
investigated by isothermal titration calorimetry (ITC), where
heat change was measured after titrating VEGF molecules into
the PA solutions (Figure 7 and Figure S11 of the Supporting
Information). The binding constants between VEGF and both
solution and nanofiber forms of Heparin-mimetic PA and Asp-PA
Figure 6. Electronmicrographs of endothelial sprouting and tube formation onHeparin-mimetic PAmatrix. (A) Cells interact with the fibrous network
and form polygonal structures. (B) Endothelial sproutings on PA matrix.
Figure 7. Calorimetric determination of interaction between Heparin-
mimetic PA and VEGF. Isothermal titration calorimetry was used to
measure binding affinity of Heparin-mimetic PA with VEGF. The top
graph shows heat change per unit time during VEGF titration into
Heparin-mimetic PA solution, and the bottom graph displays the
integrated data (filled squares) and the best fit to a nonlinear function
assuming one set of binding sites. Ka calculated =2.93  106 ( 5.12 
105 M1.
Figure 8. Slow release of growth factor from Heparin-mimetic PA gel.
Release of VEGF from 3 different PA gels were measured for 7 days.
VEGF concentration in release buffer was measured by ELISA method
(Bars indicate SEM for each group). (n = 5 for Heparin-mimetic PA; n =
3 Asp-PA and Lys-PA/heparin).
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were calculated by ITC (Figure 7, Figure S11 and Table S3 of the
Supporting Information). As a result of this experiment, binding
constant between Heparin-mimetic PA and VEGF was found to
be similar to the binding constant between heparin and VEGF,
which confirms high affinity of Heparin-mimetic PAmolecules to
VEGF. Binding constants of both solution and nanofiber forms
of PAs with VEGF were comparable as well. In addition, both
Heparin-mimetic PA and Asp-PA molecules revealed similar
binding affinity to VEGF. This suggests that VEGF-PA interac-
tion at this concentration was due to electrostatic and noncova-
lent interactions. Moreover, VEGF binding was driven by large
enthalpic changes, which also shows that hydrogen bonding,
electrostatic, and van der Waals interactions between functional
groups have taken a role in the VEGF-PA interaction (Table S3
of the Supporting Information).36 The decrease in entropy indicates
the loss of conformational freedom for interactingmolecules and the
formation ofmore ordered complex structures (Figure 7, Figure S11
and Table S3 of the Supporting Information).37
To investigate further the interaction of VEGF with the
nanofiber network formed by PA molecules, we designed a
growth factor release assay by adding VEGF to gels formed by
the PA nanofibers. VEGF release from Heparin-mimetic PA,
Asp-PA, and Lys-PA/heparin gels were monitored for 7 days to
analyze the release rate. We observed burst release of growth
factors from Asp-PA and heparin gels at 2 h, whereas the release
rate was significantly lower for Heparin-mimetic PA gels
(Figure 8). At the end of 7 days, only ∼5% of the encapsulated
VEGF was released from Heparin-mimetic PA gel, whereas this
ratio was nearly 40% for heparin gel and 33% for Asp-PA gel.
Because gelation and structural properties of the PA molecules
revealed no significant differences, as analyzed by SEM, AFM,
rheology, and CD, the possibility of physical release causing
differential release from Heparin-mimetic PA gel and other gels
was eliminated. We concluded that VEGF binds to Heparin-
mimetic PA nanofibers more strongly than Asp-PA and Lys-PA/
heparin nanofibers. Although ITC results revealed similar bind-
ing affinities for bothHeparin-mimetic PA and Asp-PAmolecules
to VEGF (Table S3 of the Supporting Information), where these
molecules are used in very dilute amounts (∼104 M), the
release of the VEGF from the corresponding gels, which are
composed of densely packed nanofibers, was significantly differ-
ent (Figure 8). According to the results of the release assay, it
can be suggested that Heparin-mimetic PA nanofibers provide
more specific binding sites for growth factors compared with
Asp-PA nanofibers. The release profile of VEGF from Lys-PA/
heparin gel further demonstrates the suppression of growth
factor binding capacity of heparin in this gel, which we have
previously hypothesized according to the results of the in vitro
angiogenesis assay (Figure 4 and Figure S7 of the Supporting In-
formation). Importantly, slow release rate of VEGF from Heparin-
mimetic PA gel is a significant finding because the formation of
robust vessels requires long-term release of growth factors at low
concentrations.24,38 Growth factor concentrations above the micro-
environmental threshold (therapeutic range) cause vessel malfor-
mation with leaky and aberrant character.24,38,39 Heparin-mimetic
PA gel was observed to release VEGFwithin the narrow therapeutic
range, which is important for clinical applications.
Angiogenesis is initiated and maintained through distinct
regulatory mechanisms that take place inside the endothelial
cells. Toward this purpose, phases of endothelial cell activa-
tion and proliferation, followed by cellular migration and finally
stabilization of tubular structures are required. Expressions of
several genes are strictly regulated during these phases. To
investigate further the mechanism of angiogenic switch in endothe-
lial cells caused by Heparin-mimetic PA nanofibers, we analyzed
the expression of genes involved in angiogenesis at mRNA level.
Six different genes were selected from three different stages of
angiogenesis. VEGF and FGF-2 are mainly involved in endothe-
lial cell activation and proliferation; integrin α5 (IA5), integrin
αv (IAV), and integrin β3 (IB3) take roles in cellular migration,
and angiopoietin-1 (Ang-1) induces stabilization of vascular
tubes.40 Endothelial cells were cultured on PA matrices for three
different durations (6, 24, and 48 h) to simulate sequential
activation of angiogenic stages in natural environment. During
the natural course of angiogenesis, VEGF and FGF-2 are upregu-
lated at 6 h, integrins at 24 h, and Ang-1 at 48 h (Table S4 of the
Supporting Information). Figure 9 shows peak points of time-
dependent transcription of each gene, where each PA treatment
Figure 9. Investigation of expression profiles of angiogenic genes in
endothelial cells (HUVEC) on Heparin-mimetic PA matrices and tissue
culture plate. Expression profiles of genes involved in different angio-
genic stages were investigated at different time points by qRT-PCR.
Activities of PA matrices tested here were compared with tissue culture
plate, and results are illustrated as change in gene expression (%). Peak
time point was selected for each gene and shown in this Figure (n = 3 for
all experiments).
Figure 10. Determination of VEGF secretion from endothelial cells
(HUVECs) cultured on PA matrices or tissue culture plate. Time-
dependent VEGF secretion from HUVECs cultured on different PA
matrices or tissue culture plate were measured by using the ELISA
method. p < 0.001 between Heparin-mimetic PA and Asp-PA or tissue
culture plate at 48 h (analyzed by two-way ANOVA) (n = 3 for all
conditions).
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was compared with the tissue culture plate. We observed that
Heparin-mimetic PA scaffold enhanced the expression of genes
for the aforementioned three stages of angiogenesis (VEGF at
6 h, IA5 and IB3 at 24 h, whereas Ang-1 at 48 h), and their mRNA
levels peaked at expected time points. FGF-2 levels were lower
than VEGF, indicating that angiogenic switch was mainly driven
by VEGF. The Asp-PA scaffold upregulated genes involved
in endothelial cell activation and migration (VEGF, IA5, IB3,
and IA5), whereas it downregulated Ang-1 (Figure 9). This
observation is consistent with in vitro tube formation results,
where Asp-PA scaffold failed to form stable tube network, which
is mainly maintained by Ang-1. Moreover, Heparin-mimetic
PA nanofibers were more potent than Asp-PA regarding the
expression of VEGF, IA5, IB3, and Ang-1, which indicates that
Heparin-mimetic PA scaffold is actively triggering endothelial
cells to enter into angiogenic route.
Because gene expression analysis in HUVECs revealed ele-
vated expression of VEGFmRNA in endothelial cells cultured on
Heparin-mimetic PA nanofibers and because capillary-like for-
mations by endothelial cells can be triggeredwithout any addition of
exogenous VEGF by using these nanofibers, we sought whether
VEGF secretion from HUVECs was also altered when cultured
on Heparin-mimetic PA nanofibers by using ELISA (Figure 10).
ELISA results revealed that time-dependent VEGF secretion
from HUVECs on Heparin-mimetic PA matrices increased expo-
nentially as a function of time. At the end of 48 h, Heparin-
mimetic PA induced four times more VEGF secretion than bare
tissue culture plate and nearly two times more than Asp-PA.
These results suggest that besides elevated expression of VEGF,
the induction of VEGF secretion is in effect. This might be due to
autocrine signaling, where released VEGF molecules from cells
are possibly entrapped and presented to the cells better with the
Heparin-mimetic PA matrix, inducing the VEGF signaling path-
ways more robustly than the Asp-PA matrix and bare tissue
culture plate.
The construction of robust vessels integrated into the circu-
latory system is crucial for functional tissue formation. To investigate
in vivo efficacy of Heparin-mimetic PA nanofibers, a rat corneal
micropocket neovascularization assay was used. Because the
cornea is devoid of blood vessels, neo-vascularization in response
to treatment condition can be easily detected.41 Our treatment
groups included Heparin-mimetic PA gel with growth factors
(VEGF/FGF-2 combination) and growth factor solution only.
Although the growth factor amount used was several times lower
than the ones that were used in the literature,42 it was sufficient
to induce neo-vascularization when used in combination with
Heparin-mimetic PA gel. Moreover, vascularization after growth
factor treatment without PA gel was significantly lower than that
induced by growth factors in combination with Heparin-mimetic
PA gel (Figure 11 and Figure S13 of the Supporting Information).
In the corneal angiogenesis assay, the samples were introduced to
the center of cornea, which is located far from the endothelial
cells, and thus there are no detectable angiogenic growth factors
in this area in healthy animals. Therefore, no significant vessel
formation was observed in animals injected with Heparin-mi-
metic PA gel without growth factor (Figure S13 of the Support-
ing Information). This observation also shows that angiogenic
activity observed in Figure 11a is not caused by inflammatory
response against PA nanofibers but is because of slow release of
growth factors from Heparin-mimetic PA gels. Moreover, Indian
ink, which was used for perfusing the animals, entered and stayed in
the newly formed capillaries, confirming that new vessels are robust
and integrated to the circulatory system.
Figure 11. Evaluation of in vivo bioactivity by corneal angiogenesis assay. (A) Injection of 1 wt % Heparin-mimetic PA gel with 10 ng of VEGF and
bFGF-induced vascularization in cornea. (B) Application of growth factor solution (10 ng of VEGF and bFGF) in physiological saline (without PA gel)
did not induce vascularization. (C) Ratio of vascularized area to total area was calculated for both groups (n = 3 for each group). Heparin-mimetic PA
gel with growth factor (Gel + GF) was significantly higher than sole growth factor (GF) solution treatment as compared with Student’s t test (p < 0.001)
(n = 3 for both treatments).
Figure 12. Suggested mechanism for induction of angiogenesis by
bioactive Heparin-mimetic PA nanofibers. Heparin-mimetic PA nano-
fibers bind to growth factors (red balls) and present them to endothelial
cells activating the angiogenic process.
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’CONCLUSIONS
In this study, the heparin need for growth factor activity was
eliminated by using heparin-mimetic peptide nanofibers deco-
rated with bioactive chemical groups (sulfonate, carboxylic acid,
and hydroxyl). Various functional groups inspired by heparin
were presented on the peptide scaffold besides the sulfonate
group. The in vitro angiogenesis assays revealed that sulfonate
group itself is not sufficient for an optimal angiogenic outcome.
By using other biologically active chemical groups along with
the sulfonate group, we were able to induce in vitro formation
of capillary-like structures by mouse and human endothelial
cells on bioactive peptide scaffold without further addition of
growth factors and other angiogenic supplements (e.g., heparin).
Endogenous angiogenic growth factors that bind to the bioactive
PA nanofibers were sufficient for vessel formation. In addition,
heparins induce more robust signaling when they are presented
to the cells in a special conformation,11,43 and Heparin-mimetic
PA nanofibers mimic this structure by presenting critical func-
tional groups of heparin appropriately and inducemore sustained
growth factor signaling (Figure 12). Proper distribution of
heparin-mimetic functional groups on the peptide nanofibers
allows specific binding to endogenous growth factors released
from cells and maintain their interaction with receptors on same
cells. Potentially, Heparin-mimetic PA nanofibers bind to heparin-
binding growth factors with a specific affinity, present them
effectively to target receptors for the formation of active growth
factorreceptor complex, and achieve sustained angiogenic signal-
ing (Figure 12). Materials presented here provide new opportu-
nities for angiogenesis and tissue regeneration by avoiding the
use of heparin and exogenous growth factors. The synthetic
scaffolds enriched with proper chemical functional groups shown
here can induce the desired physiological response for tissue
regeneration.
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